NBI-1065845Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Huntsville, Alabama, United States, 35801

Bryant, Arkansas, United States, 72022

Little Rock, Arkansas, United States, 72204

Glendale, California, United States, 91206

Los Angeles, California, United States, 90025

Oceanside, California, United States, 92056

Orange, California, United States, 92866

Pico Rivera, California, United States, 90660

San Diego, California, United States, 92103-8229

San Francisco, California, United States, 94107

San Jose, California, United States, 95124

Cromwell, Connecticut, United States, 06416

Farmington, Connecticut, United States, 06030

Hollywood, Florida, United States, 33024

Maitland, Florida, United States, 32751-5669

Maitland, Florida, United States, 32751

Miami, Florida, United States, 33174

Miami Gardens, Florida, United States, 33014

Palm Bay, Florida, United States, 32905

Tampa, Florida, United States, 33607

Tampa, Florida, United States, 33629

Atlanta, Georgia, United States, 30318

Gaithersburg, Maryland, United States, 20877

Boston, Massachusetts, United States, 02116

Watertown, Massachusetts, United States, 02472

O'Fallon, Missouri, United States, 63368

Saint Charles, Missouri, United States, 63304

Cedarhurst, New York, United States, 11516

Mount Kisco, New York, United States, 10549

New York, New York, United States, 10029

New York, New York, United States, 10128

The Bronx, New York, United States, 10461

Avon Lake, Ohio, United States, 44012

Edmond, Oklahoma, United States, 73013

Philadelphia, Pennsylvania, United States, 19104

Bellaire, Texas, United States, 77401

Dallas, Texas, United States, 75251

DeSoto, Texas, United States, 75115

Houston, Texas, United States, 77030

Stafford, Texas, United States, 77477

The Woodlands, Texas, United States, 77381

Everett, Washington, United States, 98201

Toronto, Ontario, Canada, M5H 1A1